Das macht COVID-19 bei  Diabetes so gefährlich

Schumacher, Beate

doi:10.1007/s15034-021-3735-8

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the literature has demonstrated the association between increasing age, cardiovascular risk factors, diabetes sequelae, and a more severe course of the SARS‐CoV‐2 infection 14,23,24 . From these observations follows the recommendation to lower blood glucose and HbA1c levels as a primary prevention measure to reduce the risk of severe COVID‐19 courses 25–27 . Due to lack of data on COVID‐19 symptoms in adult T1DM patients we were unable to prove this hypothesis with our current data.…”

Section: Discussionmentioning

confidence: 55%

“…14,23,24 From these observations follows the recommendation to lower blood glucose and HbA1c levels as a primary prevention measure to reduce the risk of severe COVID-19 courses. [25][26][27] Due to lack of data on COVID-19 symptoms in adult T1DM patients we were unable to prove this hypothesis with our current data. The significantly higher HbA1c in SARS-CoV-2 negatively tested patients compared to positively tested adult patients with T1DM is most likely due to a higher percentage of inpatients with diabetes manifestation (14.8 vs. 5.0%) and diabetes education (25.9 vs. 20.0%).…”

Section: T1dm In Adultsmentioning

confidence: 84%

See 1 more Smart Citation

Type 1 diabetes mellitus and SARS‐CoV‐2 in pediatric and adult patients – Data from the DPV network

Büttner

Kamrath

Karges

et al. 2022

Journal of Diabetes

View full text Add to dashboard Cite

Background Data on patients with type 1 diabetes mellitus (T1DM) and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections are sparse. This study aimed to investigate the association between SARS‐CoV‐2 infection and T1DM. Methods Data from the Prospective Diabetes Follow‐up (DPV) Registry were analyzed for diabetes patients tested for SARS‐CoV‐2 by polymerase chain reaction (PCR) in Germany, Austria, Switzerland, and Luxembourg during January 2020–June 2021, using Wilcoxon rank‐sum and chi‐square tests for continuous and dichotomous variables, adjusted for multiple testing. Results Data analysis of 1855 pediatric T1DM patients revealed no differences between asymptomatic/symptomatic infected and SARS‐CoV‐2 negative/positive patients regarding age, new‐onset diabetes, diabetes duration, and body mass index. Glycated hemoglobin A1c (HbA1c) and diabetic ketoacidosis (DKA) rate were not elevated in SARS‐CoV‐2‐positive vs. ‐negative patients. The COVID‐19 manifestation index was 37.5% in individuals with known T1DM, but 57.1% in individuals with new‐onset diabetes. 68.8% of positively tested patients were managed as outpatients/telemedically. Data analysis of 240 adult T1MD patients revealed no differences between positively and negatively tested patients except lower HbA1c. Of these patients, 83.3% had symptomatic infections; 35.7% of positively tested patients were hospitalized. Conclusions Our results indicate low morbidity in SARS‐CoV‐2‐infected pediatric T1DM patients. Most patients with known T1DM and SARS‐CoV‐2 infections could be managed as outpatients. However, SARS‐CoV‐2 infection was usually symptomatic if it coincided with new‐onset diabetes. In adult patients, symptomatic SARS‐CoV‐2 infection and hospitalization were associated with age.

show abstract

Section: Discussionmentioning

confidence: 55%